We are live on
!
Find out more
5VM
5AM Venture Management Portfolio holdings
AUM
$360M
1-Year Est. Return
345.76%
This Fund
S&P 500
This Quarter
Est. Return
-25.02%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$533M
AUM Growth
+$40.3M
(+8.2%)
Cap. Flow
+$245M
Cap. Flow
% of AUM
46.03%
Top 10 Holdings %
Top 10 Hldgs %
89.07%
Holding
18
New
2
Increased
–
Reduced
5
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PEAR
Pear Therapeutics, Inc. Class A Common Stock
PEAR
|
+$166M |
| 2 |
Entrada Therapeutics
TRDA
|
+$107M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Crinetics Pharmaceuticals
CRNX
|
+$12.3M |
| 2 |
Vor Biopharma
VOR
|
+$4.77M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$3.94M |
| 4 |
Cabaletta Bio
CABA
|
+$3.15M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$2.08M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.33% |
| 2 | Financials | 0.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PEAR
1
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
| $116M | 21.68% |
+18,631,771
| New | +$166M |
|
|
2
Entrada Therapeutics
TRDA
$282M
| $75.5M | 14.17% |
+4,408,379
| New | +$107M |
|
|
3
Vor Biopharma
VOR
$1.16B
| $73.9M | 13.87% |
318,086
-16,535
| -5% | -$4.77M |
|
4
Rallybio
RLYB
$84.6M
| $40M | 7.5% |
523,841
| – | – |
|
|
AKUS
5
DELISTED
Akouos Inc
AKUS
| $35.2M | 6.6% |
4,135,784
| – | – |
|
6
IDEAYA Biosciences
IDYA
$3.41B
| $33M | 6.2% |
1,398,066
| – | – |
|
7
Arvinas
ARVN
$520M
| $32.9M | 6.17% |
400,000
| – | – |
|
|
IMPL
8
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| $24.9M | 4.67% |
2,884,791
| – | – |
|
|
9
Crinetics Pharmaceuticals
CRNX
$8.89B
| $24.5M | 4.6% |
862,286
-500,000
| -37% | -$12.3M |
|
|
SCPH
10
DELISTED
scPharmaceuticals
SCPH
| $19.2M | 3.61% |
3,831,474
| – | – |
|
11
Q32 Bio
QTTB
$450M
| $16.5M | 3.1% |
251,996
| – | – |
|
|
ISEE
12
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $10.8M | 2.02% |
643,248
-126,752
| -16% | -$2.08M |
|
|
RNAM
13
DELISTED
Avidity Biosciences
RNAM
| $9.28M | 1.74% |
390,555
-165,000
| -30% | -$3.94M |
|
14
Janux Therapeutics
JANX
$934M
| $8.8M | 1.65% |
446,266
| – | – |
|
|
15
Cabaletta Bio
CABA
$439M
| $7.82M | 1.47% |
2,064,263
-295,000
| -13% | -$3.15M |
|
|
FVAM
16
DELISTED
5:01 Acquisition Corp
FVAM
| $3.6M | 0.67% |
365,126
| – | – |
|
|
CDTX
17
DELISTED
Cidara Therapeutics
CDTX
| $1.44M | 0.27% |
56,726
| – | – |
|
18
ARS Pharmaceuticals
SPRY
$542M
| – | – |
-169,748
| Closed | -$1.69M |
|
Similar funds
LSC
WIP
RA
SWM
NC
MCM
KLWA
PWC
5AM Venture Management's Q4 2021 Portfolio in Review
As of Q4 2021, 5AM Venture Management held 18 positions worth $533M, up 8.2% from $492M the previous quarter. Its ten largest holdings account for 89% of the portfolio.
5AM Venture Management deployed $245M of net new capital in Q4 2021, opening 2 new positions. Its largest new stake was Pear Therapeutics, Inc. Class A Common Stock: 18,631,771 shares worth $116M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Crinetics Pharmaceuticals, an estimated $12.3M trimmed.
- 5AM Venture Management's largest Q4 2021 buy was Pear Therapeutics, Inc. Class A Common Stock: 18,631,771 shares worth $116M.
- 5AM Venture Management's biggest Q4 2021 reduction was Crinetics Pharmaceuticals, cutting an estimated $12.3M.
- 5AM Venture Management fully exited ARS Pharmaceuticals in Q4 2021, selling an estimated $1.69M.
- 5AM Venture Management's ten largest holdings make up 89% of its $533M portfolio in Q4 2021.
- 5AM Venture Management opened 2 new positions and closed 1 in Q4 2021.
- 5AM Venture Management's portfolio value rose 8.2% quarter-over-quarter to $533M.
Based on 5AM Venture Management's 13F filing for Q4 2021, filed 3 Feb 2022.